Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Avacta Group
Avacta Group
Activities:
Research & Development
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
Beneo presents its taste-boosting excipient, galenIQ at CPHI 2024
galenIQ is designed to improve the flavour of oral solid dosage (OSD) forms for more patient-centric pharmaceuticals
Merck's MilliporeSigma cuts the ribbon on €290m US biosafety and analytical facility
The site will host biosafety testing, analytical development and cell banking manufacturing services
Seppic launches surfactant excipient for the optimisation of biological formulations
The ingredient is compatible with sensitive biologics, and aims to stabilise injectables for improved bioavailability, efficacy and shelf life
Strides Group launches CDMO OneSource Specialty Pharma at CPHI Milan
The newly integrated CDMO primarily specialises in the manufacture of biologics, drug-device combos and gelatin capsules
Johnson & Johnson completes V-Wave acquisition to support patients with heart failure
The strategic acquisition will bolster the pharma giant's MedTech offerings for patients with cardiovascular disease
Upcoming event
ISCC
15-18 October 2024 | Conference | Milan, Italy
See all
Related Content
Research & Development
Avacta achieves milestone in AffyXell joint venture
The second milestone will result in an increase in Avacta’s shareholding in AffyXell, which currently stands at 19%
Research & Development
AffyXell expands partnership with GenScript ProBio
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Finance
Avacta appoints Non-Executive Director to board
Christina Coughlin previously served as CMO to Rubius Therapeutics, where she led the clinical development, translational medicine and regulatory efforts for the company
Analysis
Avacta provides update on its antigen test for Omicron
The company has taken the decision to pause sales of the AffiDX antigen test while it replaces the antibody in the product to ensure its performance with the Omicron variant matches that of the previous mutations
Finance
Astrea Bioseparations invests in infrastructure in UK and Singapore
The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore
Finance
Avacta appoints Chief Scientific Officer of therapeutics division
Dr Alastair Smith, CEO of Avacta Group, commented: “We are delighted to have Fiona McLaughlin join us as Chief Scientific Officer of our therapeutics division
Finance
Avacta appoints Dr Mark Goldberg as Non-Executive Director
Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Subscribe now